Hybrid dynamic pharmacophore models as effective tools to identify novel chemotypes for anti-TB inhibitor design: A case study with Mtb-DapB
Abstract
Antimicrobial resistance (AMR) is one of the most serious global public health threats as it compromises the successful treatment of deadly infectious diseases like tuberculosis. New therapeutics are constantly needed but it takes a long time and is expensive to explore new biochemical space. One way to address this issue is to repurpose the validated targets and identify novel chemotypes that can simultaneously bind to multiple binding pockets of these targets as a new lead generation strategy. This study reports such a strategy, dynamic hybrid pharmacophore model (DHPM), which represents the combined interaction features of different binding pockets contrary to the conventional approaches, where pharmacophore models are generated from single binding sites. We have considered Mtb-DapB, a validated mycobacterial drug target, as our model system to explore the effectiveness of DHPMs to screen novel unexplored compounds. Mtb-DapB has a cofactor binding site (CBS) and an adjacent substrate binding site (SBS). Four different model systems of Mtb-DapB were designed where, either NADPH/NADH occupies CBS in presence/absence of an inhibitor 2, 6-PDC in the adjacent SBS. Two more model systems were designed, where 2, 6-PDC was linked to NADPH and NADH to form hybrid molecules. The six model systems were subjected to 200ns molecular dynamics simulations and trajectories were analyzed to identify stable ligand-receptor interaction features. Based on these interactions, conventional pharmacophore models (CPM) were generated from the individual binding sites while DHPMs were created from hybrid-molecules occupying both binding sites. A huge library of 15, 63,764 publicly available molecules were screened by CPMs and DHPMs. The screened hits obtained from both types of models were compared based on their Hashed binary molecular fingerprints and 4-point pharmacophore fingerprints using Tanimoto, Cosine, Dice and Tversky similarity matrices. Molecules screened by DHPM exhibited significant structural diversity, better binding strength and drug like properties as compared to the compounds screened by CPMs indicating the efficiency of DHPM to explore new chemical space for anti-TB drug discovery. The idea of DHPM can be applied for a wide range of mycobacterial or other pathogen targets to venture into unexplored chemical space.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 12
- FWCI
- 0.87
- Field percentile
- top 23%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In silico identification of novel chemical compounds with anti-TB potential for the inhibition of InhA and EthR from Mycobacterium tuberculosis
Sajal Kumar Halder, Fatiha Elma·Journal of Clinical Tuberculosis and Other Mycobacterial DiseasesPeer-reviewed·May 25, 2021
- Designing Novel and Potent Inhibitors for Multi Drug-Resistant Tuberculosis: A Computational Approach
Muhammad Idrees, Bashir Ahmad, … Aishma Khattak·Pakistan Journal of ZoologyPeer-reviewed·Aug 24, 2021
- Investigation of the anti-TB potential of selected alkaloid constituents using molecular docking approach
Mohammad Kawsar Sharif Siam, Mohammad Umer Sharif Shohan, Zaira Zafroon·bioRxiv·Apr 28, 2020
- In-silico Exploration of Drug Leads Targeting Mycobacterial Ag85C
Katewad Raghavendra Singh, C. M. Anuradha, Chitta Suresh Kumar·bioRxiv·Oct 1, 2026
- In silico and in vitro screening of FDA-approved drugs for potential repurposing against tuberculosis
Sridharan Brindha, Jagadish Chandrabose Sundaramurthi, … John Joel Gnanadoss·bioRxiv·Dec 3, 2017
- Discovery and Optimization of Inhibitors for the Pup Proteasome System in Mycobacterium tuberculosis
G. Janssen, R. Merkx, … H. Ovaa·bioRxiv·Oct 7, 2019